Novo Nordisk cuts sales outlook, faces securities fraud lawsuit.

• Novo Nordisk sued for securities fraud and unlawful business practices. • Class action concerns allegations of securities fraud and unlawful practices. • Investors who purchased Novo Nordisk securities during the Class Period must file a complaint by September 30, 2025. • Complaint available at www.pomerantzlaw.com. • Novo Nordisk lowered its sales outlook on July 29, 2025.

In a significant development, Novo Nordisk A/S (NYSE: NVO), the Danish pharmaceutical giant, is facing multiple securities fraud lawsuits. The lawsuits allege that the company made false and misleading statements about its business prospects, particularly concerning its GLP-1 drugs. Investors who purchased Novo Nordisk securities between May 7, 2025, and July 28, 2025, are encouraged to take action.

The Schall Law Firm, Glancy Prongay & Murray LLP, and Bernstein Liebhard LLP have all announced class action lawsuits against Novo Nordisk, citing violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5. The lawsuits allege that Novo Nordisk misrepresented the impact of the personalization exception to the compounded GLP-1 exclusion on its business, overstated its ability to capture patients from compounded treatments, and artificially inflated its growth prospects in the GLP-1 market [1][2][3].

According to the complaints, Novo Nordisk's statements were false and materially misleading throughout the class period. The lawsuits claim that when the market learned the truth about Novo Nordisk, investors suffered damages. Investors who purchased Novo Nordisk securities during this period are urged to file a complaint by September 30, 2025, to participate in the class action lawsuit [1][2][3].

The lawsuits come on the heels of Novo Nordisk lowering its sales outlook on July 29, 2025. The company cited "unexpected challenges" in its GLP-1 market, which analysts have linked to the allegations of securities fraud [4].

Investors who wish to participate in the class action lawsuit or learn more about their rights should contact the respective law firms. The Schall Law Firm can be reached at 310-301-3335, Glancy Prongay & Murray LLP at 310-201-9150, and Bernstein Liebhard LLP at 212-951-2030. More information is available on the firms' websites [1][2][3].

References:
[1] https://www.morningstar.com/news/pr-newswire/20250825la57881/nvo-investors-have-opportunity-to-lead-novo-nordisk-as-securities-fraud-lawsuit-with-the-schall-law-firm
[2] https://www.marketscreener.com/news/novo-nordisk-a-s-nvo-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-ce7c50dbd98ff023
[3] https://www.morningstar.com/news/globe-newswire/9517482/shareholder-alert-bernstein-liebhard-llp-announces-a-securities-fraud-class-action-lawsuit-has-been-filed-against-novo-nordisk-as-nyse-nvo
[4] https://www.novonordisk.com/news/2025/07/29/novo-nordisk-lowers-sales-outlook-for-2025.html